Bronchiolitis
Drug research and approvals for bronchiolitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 119 studies of bronchiolitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 5 open orphan designations naming it.
- Recruiting worldwide: 119
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 119 recruiting on ClinicalTrials.gov ↗- Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host DiseaseNCT07733141 · Not applicable · City of Hope Medical Center · starts Mar 1, 2027
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged…NCT07771439 · Phase 3 · Sanofi · starts Oct 12, 2026
- A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing…NCT07350057 · Phase 1 · Shanghai Jiao Tong University School of Medicine · starts Sep 28, 2026
- Respiratory Physiotherapy and Hospitalization in Infants With BronchiolitisNCT07682844 · Not applicable · University of Sao Paulo · starts Aug 8, 2026
- A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With…NCT07600788 · Phase 1 · Ausper Biopharma Co., Ltd. · starts Jul 9, 2026
- Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis…NCT07771855 · Phase 2 · Hopital Foch · starts Jun 24, 2026
- Study of AHB-171 in Chronic Hepatitis B ParticipantsNCT07630727 · Phase 2 · Ausper Biopharma Co., Ltd. · starts Jun 24, 2026
- Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aPNCT07380113 · Phase 4 · Zhujiang Hospital · starts Jun 22, 2026
- Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHDNCT06991361 · Phase 1 · Sarah Nikiforow, MD · starts May 29, 2026
- Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain.NCT07403500 · Not applicable · Centre Hospitalier Universitaire de Nīmes · starts May 28, 2026
Drug Pipeline
7 in phase 3, 5 in phase 2; from ChEMBL's drug indications, furthest stage reached for this condition- Dexamethasone
- Phase 3 Glucocorticoid receptor agonist
- Epinephrine
- Phase 3 Adrenergic receptor agonist
- Montelukast
- Phase 3 Cysteinyl leukotriene receptor 1 antagonist
- Furosemide
- Phase 3 Sodium-(potassium)-chloride cotransporter 2 inhibitor
- Nitric oxide
- Phase 3 Soluble guanylate cyclase activator
- Oxygen
- Phase 3 Essential for cellular homeostasis
- Zinc sulfate
- Phase 3
- Cholecalciferol
- Phase 2 Vitamin D receptor agonist
- Albuterol
- Phase 2 Beta-2 adrenergic receptor agonist
- Fluticasone propionate
- Phase 2 Glucocorticoid receptor agonist
- Phenylephrine
- Phase 2 Adrenergic receptor alpha-1 agonist
- Nitazoxanide
- Phase 2 Pyruvate:ferredoxin oxidoreductase inhibitor
How Its Trials Ended
379 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 97 whose ending is known, 29% met their primary endpoint, 23% missed it and 48% stopped early.
- Completed, result not reported15340%
- Ongoing6818%
- Status unknown6116%
- Met its primary endpoint287%
- Stopped: other or unclear257%
- Missed its primary endpoint226%
- Stopped: enrollment or feasibility123%
- Stopped: lack of efficacy31%
- Stopped: sponsor or business decision31%
- Stopped: funding31%
- Stopped: safety10%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Dec 17, 2021 | A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of bi 1291583 qd over at least…Verducatib (bi 1291583) | Boehringer Ingelheim (Canada) Ltd Ltee | Closed |
| Nov 12, 2019 | An open-label, single-arm, phase 1/2 study evaluating the safety and efficacy of itacitinib in participants with bronchiolitis obliterans syndrome following…Itacitinib (INCB039110) | Incyte | Closed |
| Jan 22, 2018 | A randomized controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitisdexamethasone/ epinephrine | Childrens Hospital Of Eastern Ontario Research Institute | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Dec 21, 2021 | SirolimusTreatment of Bronchiolitis Obliterans Syndrome | AI Therapeutics, Inc. | Designated |
| Aug 7, 2018 | Interleukin-1 receptor antagonist (IL-1Ra,…Treatment of Bronchiolitis Obliterans | Onspira Therapeutics, Inc., a wholly owned subsidiary of Sumitomo Pharma America, Inc. | Designated |
| Apr 10, 2017 | Recombinant human club cell proteinTreatment of bronchiolitis obliterans | Trove Therapeutics, Inc. | Designated |
| May 11, 2009 | Liposomal cyclosporineTreatment of bronchiolitis obliterans | Zambon S.p.A. | Designated |
| Jun 24, 2008 | Liposomal cyclosporine for inhalationPrevention of bronchiolitis obliterans. | Zambon S.p.A. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA